Directs the commissioner of social services to authorize the payment of medical assistance funds for rapid whole genome sequencing for persons under twenty-one years of age under certain medical circumstances.
Summary
This bill would add a new section to the Social Services Law directing the Commissioner of Social Services to authorize Medicaid payment for rapid whole genome sequencing for certain beneficiaries under age 21. Coverage would apply when the child has a complex or acute illness of unknown cause, is receiving hospital services in an intensive care or other high-acuity unit, and meets evidence-based medical necessity criteria. The bill defines rapid whole genome sequencing as a test of the entire human genome, including coding and non-coding regions and mitochondrial DNA, with preliminary results in seven days and final results in fifteen days.
The bill also sets detailed clinical criteria for when the test may be covered, including congenital anomalies, suspected genetic disease, refractory seizures, abnormal cardiac findings, metabolic disorders, severe muscle weakness, and other signs suggesting a genetic etiology. It allows the commissioner to expand qualifying conditions based on new medical evidence and to cover related next-generation sequencing or genetic testing if appropriate. The measure takes effect immediately, but Medicaid payment authority would begin one year after enactment and would be subject to any required federal approval from the Centers for Medicare and Medicaid Services.
Impact
The bill would amend New York’s Social Services Law by creating a new Medicaid coverage category for rapid whole genome sequencing in pediatric high-acuity cases. It would require the state Medicaid program to pay for the test under specified circumstances, while also directing the commissioner to adopt regulations, seek federal approval or state plan amendments as needed, and take other administrative steps to implement the coverage. The bill also establishes rules governing the use of genetic data, including HIPAA-based privacy protections, limits on research use without express consent, access rights for patients and guardians, and a right to revoke consent and require expungement from data repositories.
Sentiment
There is no recorded committee transcript or vote history in the provided material, so no direct legislative debate or formal sentiment can be measured from the record. Based on the bill text, the measure appears designed as a targeted health coverage expansion for seriously ill children with suspected genetic conditions, suggesting a policy rationale centered on faster diagnosis and treatment. The absence of opposition or amendments in the provided context means the overall sentiment cannot be assessed beyond the bill’s apparent clinical and patient-centered purpose.
Contention
The main potential points of contention are likely to be cost, Medicaid program administration, and the scope of eligible cases. Because the bill requires payment for an advanced and potentially expensive genetic test, fiscal concerns may arise for the state and for Medicaid administrators. Another possible issue is the detailed medical-necessity standard, including which conditions qualify and whether the commissioner should have discretion to add more conditions over time. Privacy and secondary use of genetic data could also be debated, although the bill addresses those concerns by limiting research use to cases with express consent and by tying data handling to HIPAA and related laws.
Same As
Directs the commissioner of social services to authorize the payment of medical assistance funds for rapid whole genome sequencing for persons under twenty-one years of age under certain medical circumstances.
Directs the commissioner of social services to authorize the payment of medical assistance funds for rapid whole genome sequencing for persons under twenty-one years of age under certain medical circumstances.
Directs the commissioner of social services to authorize the payment of medical assistance funds for rapid whole genome sequencing for persons under twenty-one years of age under certain medical circumstances.